In Jan 2015, the Society of Gynecologic Oncology (SGO), the American Society for Colposcopy and Cervical Pathology (ASCCP), with input from representatives of five other US national medical organizations (ACOG, ACS, ASCP, ASC, CAP) issued an Interim Guidance Report after the U.S. Food and Drug Administration (FDA) approved the cobas® HPV Test as a primary, or first, test performed for cervical cancer screening. This new guidance is in addition to the existing 2012 guidelines and specifically addresses the implementation of HPV testing in primary screening.
In Jan 2016, the American College of Obstetricians and Gynecologists (ACOG) published Practice Bulletin 157, that supports the use of cobas® HPV Test for primary cervical cancer screening as an alternative to current cytology-based cancer screening methods in women 25 years and older. In October 2016, the clinical management guidelines for cervical cancer screening and prevention were updated and Practice Bulletin 168 was issued to replace 157.
The guidance recommends: